{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:24:56.133427+00:00","company":{"ticker":"BIXT","cik":1445815,"company_name":"BIOXYTRAN, INC"},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"9ab3cc222380fc9133e88f903cb09d425bebe079","cik":1445815,"ticker":"BIXT","company_name":"BIOXYTRAN, INC","filed_at":"2026-03-13T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-02-18","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Amendment to the Certificate of Designation of Convertible Preferred Stock, effective upon filing"},"claim":"BIOXYTRAN, INC: Filed Certificate of Amendment to the Certificate of Designation of Convertible Preferred Stock, effective upon filing (effective 2026-02-18).","evidence_excerpt":"In connection with the amendment described above, the Company filed a Certificate of Amendment to the Certificate of Designation of Convertible Preferred Stock with the Nevada Secretary of State on February 18, 2026, which became effective upon filing.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-010045","anchor_url":"https://secwatch.observer/filing/0001493152-26-010045#claim-9ab3cc222380fc9133e88f903cb09d425bebe079","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1445815/000149315226010045/0001493152-26-010045-index.htm"},{"fact_type":"material_agreement","fact_key":"dcaf99c7eb68130ee2acef3f890c087213bedab8","cik":1445815,"ticker":"BIXT","company_name":"BIOXYTRAN, INC","filed_at":"2026-02-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Distribution Agreement","agreement_type":"supply","counterparty":"Khoury Medical LTD","effective_date":"2026-02-10","item_codes_triggered":["1.01"],"value_text":null},"claim":"BIOXYTRAN, INC entered into Distribution Agreement with Khoury Medical LTD (effective 2026-02-10).","evidence_excerpt":"On February 10, 2026, Bioxytran entered into a commercial Distribution Agreement, attached hereto as Exhibit 10.90, with Khoury Medical LTD","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-006891","anchor_url":"https://secwatch.observer/filing/0001493152-26-006891#claim-dcaf99c7eb68130ee2acef3f890c087213bedab8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1445815/000149315226006891/0001493152-26-006891-index.htm"},{"fact_type":"auditor_change","fact_key":"a045997259bc46f3dc4f76e7e69303ddc67f1b04","cik":1445815,"ticker":"BIXT","company_name":"BIOXYTRAN, INC","filed_at":"2025-01-13T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Fruci & Associates II, PLLC","disagreement_text":"the Company, in consultation with its Audit Committee, concluded that its previously issued Financial Statements for the years ended December 31, 2023, and 2022 should be restated because of a misapplication in the guidance around the valuation for certain of our outstanding shares of Common Stock and should no longer be relied upon.","effective_date":null,"item_codes_triggered":["4.02"],"non_reliance_signal":"non_reliance","successor_auditor_name":null},"claim":"BIOXYTRAN, INC engaged Fruci & Associates II, PLLC as its auditor.","evidence_excerpt":"the Company engaged Fruci & Associates II, PLLC (\"Fruci\"), PCAOB ID # 05525, as their successor auditor in order to re-audit the Financial Statements for the years ended December 31, 2023 and 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-001891","anchor_url":"https://secwatch.observer/filing/0001493152-25-001891#claim-a045997259bc46f3dc4f76e7e69303ddc67f1b04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1445815/000149315225001891/0001493152-25-001891-index.htm"},{"fact_type":"auditor_change","fact_key":"c366b6db584b63ff8513d67f52d86f59fcc7e9d2","cik":1445815,"ticker":"BIXT","company_name":"BIOXYTRAN, INC","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Fruci & Associates II, PLLC","disagreement_text":null,"effective_date":"2024-05-07","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"BIOXYTRAN, INC engaged Fruci & Associates II, PLLC as its auditor.","evidence_excerpt":"On May 7, 2024, Bioxytran, Inc. (the “Company”) dismissed BF Borgers CPA PC (“BF Borgers”) as its independent public accountants and appointed Fruci & Associates II, PLLC (PCAOB #5525) (“Fruci”) as its new independent accountants.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018484","anchor_url":"https://secwatch.observer/filing/0001493152-24-018484#claim-c366b6db584b63ff8513d67f52d86f59fcc7e9d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224018484/0001493152-24-018484-index.htm"},{"fact_type":"auditor_change","fact_key":"274354db7654655ba34e7c4c2d9e9f9f79764299","cik":1445815,"ticker":"BIXT","company_name":"BIOXYTRAN, INC","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"BF Borgers CPA PC","disagreement_text":null,"effective_date":"2024-05-07","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Fruci & Associates II, PLLC"},"claim":"BIOXYTRAN, INC dismissed BF Borgers CPA PC as its auditor.","evidence_excerpt":"On May 7, 2024, Bioxytran, Inc. (the “Company”) dismissed BF Borgers CPA PC (“BF Borgers”) as its independent public accountants and appointed Fruci & Associates II, PLLC (PCAOB #5525) (“Fruci”) as its new independent accountants.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018484","anchor_url":"https://secwatch.observer/filing/0001493152-24-018484#claim-274354db7654655ba34e7c4c2d9e9f9f79764299","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1445815/000149315224018484/0001493152-24-018484-index.htm"}]}